Literature DB >> 12557224

Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma.

Jan J Molenaar1, Peter van Sluis, Kathy Boon, Rogier Versteeg, Huib N Caron.   

Abstract

Cyclin D1 regulates G1 cell cycle progression by controlling the phosphorylation of the retinoblastoma protein. This pathway is frequently deregulated in many malignancies. In neuroblastoma, however, no consistent G1 cell cycle checkpoint aberrations have been found. We examined the possible deregulation of cyclin D1 (CCND1) in this tumor. mRNA expression profiles of neuroblastoma generated by SAGE (Serial Analysis of Gene Expression) revealed a high expression of CCND1 in a subset of neuroblastoma cell lines and tumors. The CCND1 expression level can be 0.3% of the total cellular mRNA. Northern blot analysis of CCND1 expression showed a relative overexpression in 16 of 23 neuroblastoma cell lines and 10 of 15 tumor samples. In the majority of cases, the high CCND1 mRNA levels also led to high CCND1 protein levels. In the search for mechanisms causing this relative overexpression, we screened for amplifications and rearrangements of CCND1. Five amplifications were found in 202 neuroblastoma tumors and cell lines. Analysis of the 3'-UTR of CCND1 showed a rearrangement in 1 of 96 tumors. These clonal aberrations of CCND1 together with the high expression suggest a role for deregulated CCND1 activity in neuroblastoma tumorigenesis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557224     DOI: 10.1002/gcc.10166

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  29 in total

1.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Authors:  Chunxi Wang; Zhihui Liu; Chan-Wook Woo; Zhijie Li; Lifeng Wang; Jun S Wei; Victor E Marquez; Susan E Bates; Qihuang Jin; Javed Khan; Kai Ge; Carol J Thiele
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

2.  Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma cells.

Authors:  Swapnil Parashram Bhavsar; Cecilie Løkke; Trond Flægstad; Christer Einvik
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967

3.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Authors:  Jan J Molenaar; Jan Koster; Danny A Zwijnenburg; Peter van Sluis; Linda J Valentijn; Ida van der Ploeg; Mohamed Hamdi; Johan van Nes; Bart A Westerman; Jennemiek van Arkel; Marli E Ebus; Franciska Haneveld; Arjan Lakeman; Linda Schild; Piet Molenaar; Peter Stroeken; Max M van Noesel; Ingrid Ora; Evan E Santo; Huib N Caron; Ellen M Westerhout; Rogier Versteeg
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

Review 4.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

5.  Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.

Authors:  Irene Y Cheung; Yi Feng; Andrew Vickers; William Gerald; Nai-Kong V Cheung
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

6.  Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Authors:  Julieann Rader; Mike R Russell; Lori S Hart; Michael S Nakazawa; Lili T Belcastro; Daniel Martinez; Yimei Li; Erica L Carpenter; Edward F Attiyeh; Sharon J Diskin; Sunkyu Kim; Sudha Parasuraman; Giordano Caponigro; Robert W Schnepp; Andrew C Wood; Bruce Pawel; Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

7.  Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Authors:  Irene Y Cheung; Yi Feng; William Gerald; Nai-Kong V Cheung
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

9.  Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients.

Authors:  Ping Xu; Mengyang Zhao; Zhen Liu; Yiyi Liu; Yiyu Chen; Rongcheng Luo; Weiyi Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 10.  Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

Authors:  Kristopher R Bosse; John M Maris
Journal:  Cancer       Date:  2015-11-05       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.